

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known	
			Application Number	10/594,163
			Filing Date	September 26, 2006
			First Named Inventor	KOYAKUMARU, Kenichi
			Group Art Unit	Unassigned
			Examiner Name	Unassigned
Attorney Docket Number	701062			
Client Reference No.	201510			
Sheet	1	of	1	

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
/S.C./	AA	4,230,625		Despreaux et al.	Oct. 28, 1980	
/S.C./	AB	4,301,246		Despreaux et al.	Nov. 17, 1981	
/S.C./	AC	6,933,383	B2	Kinney et al.	Aug. 23, 2005	
/S.C./	AD	2003/0181742	A1	Nakazawa et al.	Sep. 25, 2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No*
/S.C./	A E	JP	56-8399	A	F. Hoffman-La Roche & Co., AG.	Jan. 28, 1981		X*
/S.C./	A F	WO	01/79255	A1	Genaera Corporation	Oct. 25, 2001		
/S.C./	A G	WO	02/20552	A1	Kuraray Co., Ltd.	Mar. 14, 2002		X*
/S.C./	A H	WO	03/051904	A1	Kuraray Co., Ltd.	Jun. 26, 2003		X*

OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.				Translation	
						Yes	No**
/S.C./	AI	Kinney et al., <i>Organic Letters</i> , 2(19): 2921-2922 (2000)					
/S.C./	AJ	Kim et al., <i>Bloorganic and Medicinal Chemistry</i> , 8: 2059-2065 (2000)					
/S.C./	AK	Templeton et al., <i>J. Chem. Soc., Perkin Trans. 1</i> : 2037-2043 (1997)					

Examiner Signature	/Sara Clark/ (03/08/2009)	Date Considered	03/08/2009
--------------------	---------------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).